Abstract BACKGROUND Stereotactic radiosurgery (SRS) for benign intracranial meningiomas is an established treatment. OBJECTIVE To summarize the literature and provide evidence-based practice guidelines on behalf of the International Stereotactic Radiosurgery Society (ISRS). METHODS Articles in English specific to SRS for benign intracranial meningioma, published from January 1964 to April 2018, were systematically reviewed. Three electronic databases, PubMed, EMBASE, and the Cochrane Central Register, were searched. RESULTS Out of the 2844 studies identified, 305 had a full text evaluation and 27 studies met the criteria to be included in this analysis. All but one were retrospective studies. The 10-yr local control (LC) rate ranged from 71% to 100%. The 10-yr progression-free-survival rate ranged from 55% to 97%. The prescription dose ranged typically between 12 and 15 Gy, delivered in a single fraction. Toxicity rate was generally low. CONCLUSION The current literature supporting SRS for benign intracranial meningioma lacks level I and II evidence. However, when summarizing the large number of level III studies, it is clear that SRS can be recommended as an effective evidence-based treatment option (recommendation level II) for grade 1 meningioma.

中文翻译：

---

颅内非海绵窦良性脑膜瘤的立体定向放射外科手术：国际立体定向放射外科学会系统评价、荟萃分析和实践指南

摘要背景立体定向放射外科（SRS）治疗良性颅内脑膜瘤是一种成熟的治疗方法。目的 代表国际立体定向放射外科学会 (ISRS) 总结文献并提供循证实践指南。方法 系统回顾了 1964 年 1 月至 2018 年 4 月发表的针对良性颅内脑膜瘤 SRS 的英文文章。检索了三个电子数据库，PubMed、EMBASE 和 Cochrane Central Register。结果 在确定的 2844 项研究中，305 项进行了全文评估，27 项研究符合纳入本分析的标准。除一项外，所有研究都是回顾性研究。10 年局部控制 (LC) 率范围为 71% 至 100%。10 年无进展生存率为 55% 至 97%。处方剂量范围通常在 12 到 15 Gy 之间，以单次给药。中毒率普遍较低。结论 目前支持 SRS 治疗良性颅内脑膜瘤的文献缺乏 I 级和 II 级证据。然而，在总结大量 III 级研究时，很明显可以推荐 SRS 作为 1 级脑膜瘤的有效循证治疗方案（推荐 II 级）。